RT Journal Article
SR Electronic
T1 Distinguishing Viruses Responsible for Influenza-Like Illness
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.04.20020404
DO 10.1101/2020.02.04.20020404
A1 Spencer, Julie A.
A1 Shutt, Deborah P.
A1 Moser, Sarah K.
A1 Clegg, Hannah
A1 Wearing, Helen J.
A1 Mukundan, Harshini
A1 Manore, Carrie A.
YR 2021
UL http://medrxiv.org/content/early/2021/04/23/2020.02.04.20020404.abstract
AB The many respiratory viruses that cause influenza-like illness (ILI) are reported and tracked as one entity, defined by the CDC as a group of symptoms that include a fever of 100 degrees Fahrenheit and a cough and/or a sore throat. In the United States alone, ILI impacts 9-49 million people every year. While tracking ILI as a single clinical syndrome is informative in many respects, the underlying viruses differ in their parameters and outbreak properties. Most existing models treat either a single respiratory virus or ILI as a whole. However, there is a need for models capable of comparing several individual ILI viruses. To address this need, here we present a flexible model and simulations of epidemics for influenza, RSV, rhinovirus, seasonal coronavirus, adenovirus, and SARS/MERS, parameterized by a systematic literature review and accompanied by a global sensitivity analysis. We find that for these biological causes of ILI, their parameter values, timing, prevalence, and proportional contributions differ substantially. These results demonstrate that distinguishing the viruses that cause influenza-like illness will be an important aspect of future work on ILI diagnostics, mitigation, modeling, and preparation for future unknown pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch support provided by the U.S. Department of Energy through the Los Alamos National Laboratory. Los Alamos National Laboratory is operated by Triad National Security, LLC, for the National Nuclear Security Administration of U.S. Department of Energy (Contract No. 89233218CNA000001). LA-UR-20-21024. JAS was partially funded by the University of New Mexico College of Arts and Sciences Dissertation Excellence Fellowship.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe spreadsheets that contain the details of our parameter review are included in the paper, after the reference section.